Adenosine phosphate
Adenosine (adenosine phosphate) is a small molecule pharmaceutical. Adenosine phosphate was first approved as Adenocard on 1989-10-30. It is known to target transient receptor potential cation channel subfamily M member 4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Adenosine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ADENOCARD | Astellas Pharma | N-019937 DISCN | 1989-10-30 | 1 products, RLD |
| ADENOSCAN | Astellas Pharma | N-020059 DISCN | 1995-05-18 | 2 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| adenosine | ANDA | 2024-05-09 |
| anyi beauty 7 days ginger germinal oil | C200263 | 2024-04-29 |
| anyi beauty kojic acid brightening serum | C200263 | 2024-04-29 |
| anyi beauty peptides facial serum | C200263 | 2024-04-29 |
| anyi beauty turmeric face serum | C200263 | 2024-04-29 |
| anyi beauty vitamin c super serum | C200263 | 2024-04-27 |
| autophagy revolution serum | unapproved drug other | 2024-02-22 |
| autophagy revolutioncream | unapproved drug other | 2024-02-22 |
| dpc pink aura cushion no.21 | OTC monograph not final | 2017-08-24 |
| dpc pink aura cushion no.23 | OTC monograph not final | 2017-08-24 |
Show 15 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
Code | Description |
|---|---|
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) |
Clinical
Clinical Trials
789 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronary artery disease | D003324 | — | I25.1 | 7 | 14 | 20 | 17 | 74 | 128 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 35 | 49 | 25 | 1 | 11 | 109 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | 5 | 12 | 18 | 13 | 42 | 86 |
| Coronary disease | D003327 | — | — | 2 | 9 | 15 | 9 | 29 | 62 |
| Neoplasms | D009369 | — | C80 | 16 | 21 | 1 | 1 | 1 | 34 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 5 | 12 | 11 | 1 | 1 | 29 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | 4 | 3 | 3 | 19 | 28 |
| Infarction | D007238 | EFO_0009463 | — | — | 4 | 3 | 3 | 18 | 27 |
| Ischemia | D007511 | EFO_0000556 | — | 1 | 2 | 1 | 3 | 17 | 23 |
| Heart failure | D006333 | HP_0001635 | I50 | 4 | 11 | 4 | 1 | 6 | 23 |
Show 62 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 11 | 22 | 3 | — | — | 31 |
| Lymphoma | D008223 | — | C85.9 | 7 | 22 | 1 | — | — | 27 |
| Non-small-cell lung carcinoma | D002289 | — | — | 8 | 12 | 2 | — | — | 21 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 4 | 15 | 1 | — | — | 19 |
| Carcinoma | D002277 | — | C80.0 | 8 | 10 | 2 | — | — | 18 |
| Lymphoid leukemia | D007945 | — | C91 | 4 | 13 | 2 | — | — | 18 |
| Severe combined immunodeficiency | D016511 | HP_0004430 | D81.0 | 8 | 8 | 2 | — | 7 | 18 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | 7 | 3 | — | 2 | 14 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 4 | 7 | 2 | — | — | 13 |
| Immunologic deficiency syndromes | D007153 | HP_0002721 | D84.9 | 4 | 6 | 2 | — | 5 | 13 |
Show 47 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 6 | 11 | — | — | — | 13 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 2 | 9 | — | — | 1 | 11 |
| Triple negative breast neoplasms | D064726 | — | — | 6 | 6 | — | — | — | 11 |
| Colorectal neoplasms | D015179 | — | — | 6 | 7 | — | — | 1 | 10 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 4 | 7 | — | — | — | 9 |
| Chest pain | D002637 | HP_0100749 | R07.9 | — | 1 | — | — | 8 | 9 |
| Multiple myeloma | D009101 | — | C90.0 | 2 | 6 | — | — | — | 8 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 3 | 4 | — | — | 2 | 8 |
| Inflammation | D007249 | MP_0001845 | — | 3 | 4 | — | — | 2 | 8 |
| Adenocarcinoma | D000230 | — | — | 3 | 5 | — | — | — | 7 |
Show 119 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperemia | D006940 | EFO_0003822 | H34.82 | 1 | — | — | — | 3 | 4 |
| Magnetic resonance imaging | D008279 | — | — | 1 | — | — | — | 3 | 4 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | 3 | — | — | — | — | 3 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | 2 | 3 |
| Coronary angiography | D017023 | — | — | 1 | — | — | — | 1 | 2 |
| Vasodilation | D014664 | — | — | 1 | — | — | — | 1 | 2 |
| Hepatic insufficiency | D048550 | — | — | 2 | — | — | — | — | 2 |
| Lung transplantation | D016040 | — | — | 2 | — | — | — | — | 2 |
| Primary myelofibrosis | D055728 | — | D47.4 | 1 | — | — | — | — | 1 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 1 | — | — | — | — | 1 |
Show 30 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pathologic constriction | D003251 | — | — | — | — | — | — | 8 | 8 |
| Cough | D003371 | HP_0012735 | R05 | — | — | — | — | 3 | 3 |
| Chronic cough | D000096822 | — | R05.3 | — | — | — | — | 3 | 3 |
| Syncope | D013575 | HP_0012668 | G90.01 | — | — | — | — | 3 | 3 |
| Hypertrophy | D006984 | EFO_0002460 | — | — | — | — | — | 3 | 3 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 2 | 2 |
| Septic shock | D012772 | — | A48.3 | — | — | — | — | 2 | 2 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | — | 2 | 2 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 2 | 2 |
| Panic disorder | D016584 | EFO_0004262 | F41.0 | — | — | — | — | 2 | 2 |
Show 126 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Adenosine phosphate |
| INN | adenosine phosphate |
| Description | Adenosine 5'-monophosphate is a purine ribonucleoside 5'-monophosphate having adenine as the nucleobase. It has a role as an EC 3.1.3.11 (fructose-bisphosphatase) inhibitor, an EC 3.1.3.1 (alkaline phosphatase) inhibitor, an adenosine A1 receptor agonist, a nutraceutical, a micronutrient, a fundamental metabolite and a cofactor. It is an adenosine 5'-phosphate and a purine ribonucleoside 5'-monophosphate. It is a conjugate base of an adenosine 5'-monophosphate(1+). It is a conjugate acid of an adenosine 5'-monophosphate(2-). |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O |
Identifiers
| PDB | — |
| CAS-ID | 61-19-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL752 |
| ChEBI ID | 16027 |
| PubChem CID | 6083 |
| DrugBank | DB00131 |
| UNII ID | 415SHH325A (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 349,758 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,245 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use